SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer.

BACKGROUND The analysis of bodily fluids using SELDI-TOF MS has been reported to identify signatures of spectral peaks that can be used to differentiate patients with a specific disease from normal or control patients. This report is the 2nd of 2 companion articles describing a validation study of a SELDI-TOF MS approach with IMAC surface sample processing to identify prostatic adenocarcinoma. METHODS We sought to derive a decision algorithm for classification of prostate cancer from SELDI-TOF MS spectral data from a new retrospective sample cohort of 400 specimens. This new cohort was selected to minimize possible confounders identified in the previous study described in the companion paper. RESULTS The resulting new classifier failed to separate patients with prostate cancer from biopsy-negative controls; nor did it separate patients with prostate cancer with Gleason scores <7 from those with Gleason scores > or =7. CONCLUSIONS In this, the 2nd stage of our planned validation process, the SELDI-TOF MS-based protein expression profiling approach did not perform well enough to advance to the 3rd (prospective study) stage. We conclude that the results from our previous studies-in which differentiation between prostate cancer and noncancer was demonstrated-are not generalizable. Earlier study samples likely had biases in sample selection that upon removal, as in the present study, resulted in inability of the technique to discriminate cancer from noncancer cases.

[1]  E. Schiffer.  Biomarkers for prostate cancer , 2007, World Journal of Urology.

[2]  M. Girolami,et al.  Clinical proteomics: A need to define the field and to begin to set adequate standards , 2007, Proteomics. Clinical applications.

[3]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[4]  Ian Eardley,et al.  Urinary biomarker profiling in transitional cell carcinoma , 2006, International journal of cancer.

[5]  T W Randolph,et al.  Multiscale Processing of Mass Spectrometry Data , 2006, Biometrics.

[6]  H. Mischak,et al.  Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis , 2006, Nature Medicine.

[7]  H. Mischak,et al.  Detection of Acute Tubulointerstitial Rejection by Proteomic Analysis of Urinary Samples in Renal Transplant Recipients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  M. Trosset,et al.  Discrete serum protein signatures discriminate between human retrovirus-associated hematologic and neurologic disease , 2005, Leukemia.

[9]  D. Ransohoff.  Lessons from controversy: ovarian cancer screening and serum proteomics. , 2005, Journal of the National Cancer Institute.

[10]  S. Fisher,et al.  Toward defining the human parotid gland salivary proteome and peptidome: identification and characterization using 2D SDS-PAGE, ultrafiltration, HPLC, and mass spectrometry. , 2005, Biochemistry.

[11]  William E Grizzle,et al.  Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  D. Ransohoff.  Bias as a threat to the validity of cancer molecular-marker research , 2005, Nature reviews. Cancer.

[13]  Upender Manne,et al.  The Need for Review and Understanding of SELDI/MALDI Mass Spectroscopy Data Prior to Analysis , 2005, Cancer informatics.

[14]  D. Chan,et al.  Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. , 2005, Clinical chemistry.

[15]  Joseph A. Smith,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level ⩽4.0 ng per milliliter , 2004 .

[16]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[17]  E. Diamandis.  Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. , 2004, Journal of the National Cancer Institute.

[18]  D. McCarthy,et al.  Serum Protein Expression Profiling for Cancer Detection: Validation of a SELDI-Based Approach for Prostate Cancer , 2004, Disease markers.

[19]  J. Potter,et al.  A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. , 2003, Biostatistics.

[20]  P. Schellhammer,et al.  Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. , 2002, Clinical chemistry.

[21]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[22]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[23]  J. Friedman.  Special Invited Paper-Additive logistic regression: A statistical view of boosting , 2000 .

[24]  E. Feuer,et al.  Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. , 1999, Journal of the National Cancer Institute.

[25]  F. Rabbani,et al.  Trends in poorly differentiated prostate cancer 1973 to 1994: observations from the Surveillance, Epidemiology and End Results database. , 1998, The Journal of urology.

[26]  J. Oesterling,et al.  Percent free prostate-specific antigen: the next frontier in prostate-specific antigen testing. , 1998, Urology.

[27]  R. Lamerz,et al.  Screening for prostatic carcinoma with prostate specific antigen. , 1997, Anticancer research.

[28]  Yoav Freund,et al.  Experiments with a New Boosting Algorithm , 1996, ICML.

[29]  J. Oesterling,et al.  The clinical usefulness of prostate specific antigen: update 1994. , 1994, The Journal of urology.

[30]  W. Catalona,et al.  Comparison of different serum prostate specific antigen measures for early prostate cancer detection , 1994 .

[31]  W. Catalona,et al.  Comparison of different serum prostate specific antigen measures for early prostate cancer detection. , 1994, Cancer.

[32]  J. Goméz,et al.  Serum prostate specific antigen as pre-screening test for prostate cancer. , 1992, The Journal of urology.

[33]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[34]  W. Cooner,et al.  Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. , 1990, The Journal of urology.